Reuters: EU intends to start negotiations on the purchase of “Sputnik V”

The European Union plans to begin negotiations on the purchase of the Russian Sputnik V coronavirus vaccine in order to implement a vaccination program for the European population. This was reported by Reuters, citing an EU official who is in talks with vaccine manufacturers on behalf of the community.

The EU representative recalled that Hungary and Slovakia have already approved the Russian vaccine, the Czech Republic is interested in supplying the drug. In addition, he said, Italy is considering the possibility of producing a vaccine at the ReiThera plant.

The EU has previously approved vaccines from Moderna, AstraZeneca, Pfizer and BioNTech and Johnson & Johnson. Sputnik V is undergoing examination by the European Medicines Agency. The Sputnik V vaccine was developed by the Gamaleya Center, it was registered in Russia in August 2020. The drug has been approved by more than 50 countries. According to the developer, the efficiency is over 90%.

Read more about the vaccination campaign in the world – in the material of “Kommersant” “Anti-deeds are happening around vaccines.”